Core outcome sets in cancer clinical trials: current status and future opportunities—an EORTC perspective

Background
Inconsistent, varied and selective outcome reporting is problematic in clinical trials. Core outcome sets (COS) standardise the outcomes that should be measured and reported in all trials in a specific area of health or health care. We reviewed available cancer COS and assessed their uptake in cancer clinical trials through surveying members of the European Organisation for Research and Treatment of Cancer (EORTC).

Methods
This study employs an exploratory cross-sectional design across two phases. The Core Outcome Measures in Effectiveness Trials (COMET) Initiative database was searched for cancer-specific COS on June 1st, 2023. Awareness and use of COS amongst EORTC trialists was assessed in November 2023 via an online survey.

Results
We identified a total of 85 cancer-related COS on the COMET database. Of these, 69 related to the tumour types as categorised by the EORTC and their disease orientated groups. A total of 710 EORTC members responded, of whom half (50%) stated they were unfamiliar with COS. Relevant COS were available to over a quarter of respondents, with a tenth utilising available COS. Those who chose not to use an available COS cited volume of outcomes, lack of time and infrastructure for implementation as key barriers.

Conclusions
While COS are becoming increasingly available to, and acknowledged by, cancer clinical trialists, their implementation is currently still limited. Our findings indicate that further development of COS to fill gaps for missing tumour types, greater involvement of trialists in the COS development process, and increased awareness and understanding of COS amongst trialists are all required to ensure widespread implementation of COS in cancer clinical trials.

Contributors

Ailbhe Lawlor, Steven MacLennan, Jan Bogaerts, Saskia Litiere, Vassilis Golfinopoulos, Jens Lehmann, Petr Szturz, Paula Williamson & Mieke Van Hemelrijck

Publication

Journal: Trials
Volume: 26
Issue: 129
Pages: -
Year: 2025
DOI: 10.1186/s13063-025-08812-y

Further Study Information

Current Stage: Completed
Date:
Funding source(s): None


Health Area

Disease Category: Cancer

Disease Name:

Target Population

Age Range: 18 - 69

Sex: Either

Nature of Intervention: Any

Stakeholders Involved

Study Type

- Systematic review of core outcome sets

Method(s)

- Systematic review

Linked Studies

    No related studies


Related Links

    No related links